Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

By M. Castro, S. Mathur, F. Hargreave, L. Boulet, F. Xie, James Young, H. J. Wilkins, T. Henkel, Parameswaran Nair. American Journal of Respiratory and Critical Care Medicine, 2011

651 citations recorded by the source corpus.

Subfields: Physiology, Sociology and Political Science, Surgery

View Paper: https://www.semanticscholar.org/paper/877194fc01e279a5fa3fba367e0654c732c81bab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Dyer
2. H. Rosenberg
3. P. Foster

Citations in the corpus

• Eosinophils: changing perspectives in health and disease (2012, background): “Humanized IL-5-specific monoclonal antibodies (namely, mepolizumab and reslizumab) and a humanized IL-5Rα-specific monoclonal antibody (namely, benralizumab) are under exploration for the therapeutic management of dysregulated eosinophilia [92] [93] [94] [95] [96] 125 .”